This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioMarin Receives Positive Opinion From The CHMP In The European Union For VIMIZIM(TM) (elosulfase Alfa) For Morquio A Syndrome

SAN RAFAEL, Calif., Feb. 20, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the company's Marketing Authorization Application (MAA) for VIMIZIMâ„¢ (elosulfase alfa) for the treatment of Morquio A syndrome, also called Mucopolysaccharidosis Type IVA (MPS IVA). The CHMP's recommendation is now referred to the European Commission (EC). If approved by the EC, BioMarin would receive marketing authorization for VIMIZIM in all EU Member States. The EC is expected to render a final decision for VIMIZIM in the second quarter of 2014.

"This positive CHMP opinion is an important milestone in our mission to provide the first approved therapy to treat Morquio A patients across Europe. We will leverage our existing European infrastructure to ensure that these patients gain access to VIMIZIM as quickly as possible," said Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin. "We are grateful for the continuous support we have received from the Morquio A community, and in particular, those patients who participated in the clinical development of VIMIZIM and their families."

"As a treating physician, the CHMP opinion is meaningful news for Morquio A patients who currently have no specific drug treatment option beyond supportive care," said Christian J. Hendriksz, Salford Royal NHS Foundation Trust. "VIMIZIM improved endurance in clinical trials, which may change the course of this devastating disease."

The U.S. Food and Drug Administration (FDA) approved VIMIZIM for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) on February 14, 2014.

VIMIZIM is an enzyme replacement therapy for the treatment of patients with the lysosomal storage disorder Morquio A syndrome, which is an ultra-rare, severely debilitating disease that affects an estimated 3,000 patients in the developed world. VIMIZIM is the first approved drug treatment for Morquio A syndrome.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs